Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-3 is a dual inhibitor targeting CYP51 and PD-L1, exhibiting potent antifungal activity with IC50 values of 0.205 μM and 0.039 μM, respectively. This compound induces early apoptosis in fungal cells by reducing levels of intracellular IL-2, NLRP3, and NF-κBp65 proteins. Additionally, CYP51/PD-L1-IN-3 causes mitochondrial damage and reactive oxygen species (ROS) accumulation, ultimately resulting in fungal lysis and cell death. This compound serves as a valuable tool for research in fungal infections and immune modulation. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-2 is a quinazoline compound that functions as a dual inhibitor of CYP51 and PD-L1, exhibiting IC50 values of 0.263 μM and 0.017 μM, respectively. It displays notable antifungal activity by triggering early apoptosis in fungal cells, leading to significant reductions in intracellular IL-2, NLRP3, and NF-κBp65 protein levels. Additionally, CYP51/PD-L1-IN-2 induces mitochondrial damage and reactive oxygen species (ROS) accumulation, culminating in fungal lysis and subsequent cell death. This compound is valuable for research exploring antifungal mechanisms and cancer immunotherapy. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-1 is a dual inhibitor targeting both CYP51 and PD-L1, exhibiting an IC50 of 0.884 μM for CYP51 and 0.083 μM for PD-L1. This quinazoline compound demonstrates notable antifungal activity by inducing early apoptosis in fungal cells while significantly reducing intracellular levels of IL-2, NLRP3, and NF-κBp65. Additionally, CYP51/PD-L1-IN-1 contributes to mitochondrial damage and reactive oxygen species (ROS) accumulation, ultimately leading to fungal lysis and cell death. This compound is valuable for research focused on antifungal therapies and immune modulation. -
CXCR Inhibitor
Corydalmine hydrochloride is a potent CXCR inhibitor that demonstrates significant biological activity by inhibiting spore germination in certain plant pathogenic and saprophytic fungi. Additionally, it exhibits notable analgesic properties, effectively alleviating Vincristine-induced neuropathic pain in murine models. This effect is mediated through the inhibition of the NF-κB-dependent CXCL1/CXCR2 signaling pathway, highlighting its potential applications in pain management research and fungal inhibition studies. -
IKKε/TBK-1 Inhibitor
MRT67307 dihydrochloride is a potent inhibitor of IKKε and TBK-1, demonstrating IC50 values of 160 nM and 19 nM, respectively. Additionally, this compound inhibits ULK1 and ULK2 with IC50s of 45 nM and 38 nM, respectively. MRT67307 dihydrochloride plays a significant role in blocking autophagy in cellular environments, making it a valuable tool for studies involving inflammation and autophagic processes. -
IKKε Inhibitor
IKKε-IN-1 is a selective inhibitor of IKKε, a key enzyme involved in the NF-κB signaling pathway. This compound effectively reduces cell viability, inhibits colony formation, and diminishes cell migration in various cancer cell lines. Additionally, IKKε-IN-1 induces autophagy, illustrating its potential as a research tool in the study of multiple cancer types, including colorectal, hepatocellular, bladder, breast, lung, and cervical cancers. -
Carnitine Palmitoyltransferase I Upregulator, Peroxisome Proliferator-Activated Receptor α Upregulator, Nuclear Factor Erythroid 2-Related Factor 2 Activator, Nuclear Factor-Kappa B Inhibitor, Nuclear Factor Kappa B Kinase Subunit Beta Inhibitor, Sterol Regulatory Element-Binding Protein 1 Downregulator, Acetyl-CoA Carboxylase Downregulator, Acyl-CoA:Cholesterol Acyl Transferase 1 Inhibitor, Acyl-CoA:Cholesterol Acyl Transferase 2 Inhibitor
Esculeogenin A is a potent upregulator of Carnitine Palmitoyltransferase I and Peroxisome Proliferator-Activated Receptor α, while also acting as an activator of Nuclear Factor Erythroid 2-Related Factor 2. This compound exhibits key biological activities, including hepatoprotective, hypolipidemic, and antioxidant effects. Esculeogenin A modulates essential molecular targets such as SREBP1, NF-κB, and ACAT1/ACAT2, leading to enhanced hepatic fatty acid oxidation and diminished inflammation. It is applicable in research focused on nonalcoholic fatty liver disease, atherosclerosis, and hyperlipidemia, showcasing its potential to improve liver function and mitigate the risk of associated metabolic disorders. -
COX-2 Inhibitor/PPAR-γ Activator
Zaltoprofen sulfoxide is a selective COX-2 inhibitor with an IC50 of 45.38 nM, as well as a PPAR-γ activator. This compound effectively inhibits NF-κB and MAPK inflammatory signaling pathways, making it a valuable tool in the study of inflammation and acute lung injury models. It is particularly relevant for research focused on LPS-induced acute lung injury. -
TrxR1 Inhibitor
Aurothioglucose is a potent inhibitor of thioredoxin reductase 1 (TrxR1), exhibiting an IC50 value of 65 nM. This compound effectively inhibits the DNA binding activity of NF-κB in vitro, highlighting its role in modulating key transcriptional pathways. Additionally, Aurothioglucose demonstrates anti-HIV and anti-rheumatic properties, making it a valuable reagent for research in infectious diseases and autoimmune disorders. -
ROS Inhibitor
Isodeoxyelephantopin is a sesquiterpene lactone with a primary mechanism as a reactive oxygen species (ROS) inhibitor. It demonstrates significant biological activity by inducing ROS generation and suppressing NF-κB activation, thereby contributing to its anticancer properties. Additionally, Isodeoxyelephantopin modulates long non-coding RNA (LncRNA) expression, making it a valuable reagent for breast cancer research and related fields. -
IKKβ Inhibitor
IKKβ-IN-7 is a selective inhibitor of IKKβ, exhibiting an IC50 value of 9.44 μM. This compound induces DNA damage, S-phase cell cycle arrest, and apoptosis, while also promoting reactive oxygen species accumulation and loss of mitochondrial membrane potential. By inhibiting the phosphorylation of p65 and IκBα, IKKβ-IN-7 effectively restricts p65 nuclear translocation and modulates NF-κB-regulated gene expression. This agent demonstrates significant antitumor activity in xenograft models, particularly in colorectal cancer, while exhibiting low cytotoxicity in normal cells. IKKβ-IN-7 serves as a valuable tool for research in the field of colorectal cancer. -
NF-κB Inhibitor/TRP Modulator
Cannabitwinol is a selective NF-κB inhibitor and thermosensitive TRP modulator. It effectively inhibits TNFα-induced NF-κB-driven transcription and IL-8 release, exhibiting notable anti-inflammatory and antioxidant properties. Cannabitwinol selectively activates cold-activated TRP channels, such as TRPA1 (EC50 = 3.0 μM), while antagonizing TRPM8 (IC50 = 3.9 μM), with minimal interaction with heat-activated TRP channels like TRPV1 and TRPV2. This compound is applicable in research focused on inflammatory skin diseases, cold allodynia, and hyperalgesia. -
NF-κB Inhibitor
Bengamide B is a potent inhibitor of NF-κB with an IC50 of 85 nM. This compound effectively reduces LPS-induced expression of pro-inflammatory cytokines, including TNF-α, IL-6, and MCP-1, demonstrating significant anti-inflammatory activity. Additionally, Bengamide B displays antitumor efficacy, with an IC50 of 2 nM against HCT-116 colorectal cancer cells, making it a valuable reagent for research in inflammation and oncology. -
SEAP Inhibitor
Cycloepoxydon is a potent inhibitor of secreted alkaline phosphatase (SEAP) expression, targeting both NF-κB and AP-1 signaling pathways. It effectively reduces PMA-induced SEAP expression with IC50 values ranging from 1-2 μg/mL (4.2-8.4 μM) for NF-κB and 3-5 μg/mL (12.6-21 μM) for AP-1. This compound is valuable for research applications involving inflammation, cancer biology, and signal transduction studies. -
NF-κB Inhibitor
2,4,5-Trimethoxybenzoic acid is an NF-κB inhibitor with notable anti-inflammatory properties. This compound, derived from purple perilla extracts, effectively inhibits LPS-induced inflammatory responses by blocking the activation of NF-κB and STAT signaling pathways. It has been shown to suppress M1 macrophage phenotype-mediated inflammation, making it a valuable tool for research into diabetes and related inflammatory conditions. -
IKKε/TBK-1 Inhibitor
MRT67307 hydrochloride is a selective inhibitor of IKKε and TBK-1, exhibiting IC50 values of 160 nM and 19 nM, respectively. Additionally, it inhibits ULK1 and ULK2 with IC50s of 45 nM and 38 nM, respectively. This compound is employed in research to study autophagy regulation and related cellular processes. It is particularly useful in investigations of inflammatory signaling pathways and cancer biology. -
LUBAC Inhibitor
HOIPIN-8 is a highly potent inhibitor of the linear ubiquitin chain assembly complex (LUBAC), exhibiting an IC50 value of 11 nM. As a derivative of HOIPIN-1, it offers significantly enhanced inhibition, demonstrating a 255-fold increase in potency for petit-LUBAC, along with 10-fold and 4-fold increases in inhibiting LUBAC and TNF-α-mediated NF-κB activation, respectively. HOIPIN-8 serves as an essential research tool for investigating the cellular functions of LUBAC and its role in various biological processes. -
NF-κB/PON1 Pathway Inhibitor
NF-κB/PON1-IN-1 is an NF-κB/PON1 pathway inhibitor that exhibits pronounced antioxidant properties with an IC50 of 45.76 µM. This compound demonstrates hepatoprotective activity, making it valuable for research focused on inflammation and oxidative stress. Its mechanism of action positions it as a potential therapeutic tool in studies investigating liver-related diseases and cellular protection. -
RANKL Inhibitor
RANKL-IN-2 is a selective inhibitor of RANKL, exhibiting Kd values of 3.21 μM and 4.625 μM in surface plasmon resonance and microscale thermophoresis assays, respectively. By binding to RANKL, it disrupts the RANKL-RANK interaction, thereby suppressing osteoclastogenesis through the inhibition of reactive oxygen species, MAPK, and NF-κB signaling pathways. RANKL-IN-2 demonstrates efficacy in preventing RANKL-induced osteoclast formation, bone resorption, and the expression of osteoclast-specific genes and proteins in vitro. Additionally, RANKL-IN-2 has shown potential in preventing bone loss in ovariectomized mouse models, making it a valuable tool for osteoporosis research. -
IRAK4 Inhibitor
UR241-2 is a selective inhibitor of IRAK4, targeting the IL-1–induced IRAK1/4 signaling pathway. It effectively suppresses NF-κB activation and the phosphorylation of p65 and p38, contributing to a reduction in leukemia stem cell clonogenicity. UR241-2 also serves as a valuable ligand for developing PROTAC degraders targeting IRAK4, making it a suitable tool for research in acute myeloid leukemia. -
Carbonic Anhydrase Inhibitor
(E)-Dehydrodiconiferyl alcohol is a dual inhibitor of human carbonic anhydrases IX and XII. This compound demonstrates significant biological activity by inhibiting NF-κB nuclear translocation in the connective tissues of healing areas. Its unique mechanism supports research in cancer biology and therapeutic approaches for inflammatory conditions. -
BRD 4/p38α/BRDT Inhibitor
SB-284851-BT is a selective inhibitor of BRD4, p38α, and BRDT. It effectively inhibits BRD4-BD1 with an IC50 of 1.7 µM, p38α with a Kd of 0.47 nM, and exhibits additional inhibitory activity against BRDT and BRD4 with IC50 values of 18 µM and 3.7 µM, respectively. SB-284851-BT significantly reduces IL-8 production through p38α inhibition and downregulates crucial oncogenic pathways such as c-Myc and NF-κB via BRD4 inhibition. This compound has potential applications in cancer research and therapeutic development targeting cellular signaling pathways. -
BRD4 BD1 Inhibitor
ZL0516 is a selective inhibitor of the BRD4 bromodomain 1 (BD1), demonstrating potent activity in modulating epigenetic regulation. It effectively suppresses inflammatory bowel disease (IBD) through inhibition of the BRD4/NF-κB signaling pathway, which plays a critical role in inflammation and immune responses. This compound is primarily utilized in research focusing on the development of therapeutic strategies for IBD and related inflammatory conditions. -
Inflammatory Pathway Inhibitor, Oxidative Stress Inhibitor, Cancer Pathway Inhibitor
Matairesinol is an orally active bioactive compound that functions as an inflammatory pathway, oxidative stress, and cancer pathway inhibitor. It effectively inhibits the phosphorylation of MAPK, JNK, and NF-κB, while downregulating RANKL-induced NFATc1 expression and activity, and suppressing the activation of the PI3K/AKT/FOXO1 pathway. Matairesinol is applicable in research on sepsis-mediated brain injury, osteoporosis, heart failure, atopic dermatitis, and various cancer models. -
JNK Inhibitor
Salicortin is a phenolic glycoside that functions as a JNK inhibitor. It effectively inhibits osteoclast differentiation and bone resorption by down-regulating the JNK and NF-κB/NFATc1 signaling pathways. Salicortin exhibits a range of biological activities, including anti-amnesic, anti-adipogenic, and immune-modulatory effects, making it a valuable tool for research in bone metabolism, neurobiology, and immunology. -
NF-κB Inhibitor
Esculentoside H (EsH) is a saponin with inhibitory effects on the NF-κB signaling pathway. It exhibits notable anti-tumor activity, primarily through the modulation of TNF release. EsH has been shown to suppress colon cancer cell migration by inhibiting JNK1/2 and reducing the expression of matrix metalloproteinases-9 (MMP-9), making it a valuable tool for research in cancer biology and therapeutic interventions. -
NF-κB/AP-1 Inhibitor
IQ-1S is an inhibitor of NF-κB and activating protein 1 (AP-1), exhibiting an IC50 of 1.8 μM. It demonstrates significant binding affinity for all three JNK isoforms, with Kd values of 87 nM for JNK3, 360 nM for JNK2, and 390 nM for JNK1. IQ-1S is valuable for researchers investigating the role of JNK signaling pathways and their implications in inflammation and cancer. -
JNK2 Inhibitor
JNK2-IN-1 is a selective inhibitor of JNK2, displaying a dissociation constant (Kd) of 79.2 μM. This compound exhibits anti-inflammatory properties by reducing the secretion of pro-inflammatory cytokines TNF-α and IL-6 through the inhibition of the NF-κB/MAPK signaling pathway. JNK2-IN-1 has demonstrated therapeutic potential in alleviating symptoms associated with LPS-induced acute lung injury (ALI) and sepsis, making it valuable for research in inflammation and related diseases. -
NF-κB p65 Inhibitor, p38 MAPK Inhibitor
PSMα3 is an inhibitor of NF-κB p65 and p38 MAPK, playing a significant role in modulating inflammatory pathways. This compound forms membrane pores and interacts with the human insulin B chain, inhibiting insulin aggregation and contributing to cytotoxic effects through α-type amyloid-like fibril formation. PSMα3 is valuable for research on spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and infections caused by Staphylococcus aureus. -
NF-κB/MAPK Inhibitor
NF-κB/MAPK-IN-1 is a potent inhibitor of the NF-κB and MAPK signaling pathways, exhibiting significant biological activity in the modulation of inflammatory responses. It effectively reduces nitric oxide (NO) production with an IC50 of 6.96 µM and inhibits the activation of iNOS, COX-2, ERK, and p38 signaling pathways induced by LPS. This compound is valuable for research applications focused on inflammatory diseases, including rheumatoid arthritis. -
NF-κB/MMP9/MAPK Inhibitor
Isoliquiritin apioside is an inhibitor of NF-κB, MMP9, and MAPK signaling pathways. It has been shown to significantly reduce PMA-induced MMP9 activity and suppress the activation of MAPK and NF-κB. This compound is relevant for research applications focused on cancer biology, particularly in the investigation of mechanisms underlying cell invasiveness and angiogenesis in both cancer and endothelial cells. -
PDE4 Inhibitor
Glaucine, a selective phosphodiesterase 4 (PDE4) inhibitor, is an alkaloid sourced from Glaucium flavum. It demonstrates significant biological activities such as bronchodilation, anti-inflammatory effects, and anticancer properties. With a Ki of 3.4 µM in human bronchial tissues and polymorphonuclear leukocytes, Glaucine promotes relaxation of isolated human bronchi through calcium channel antagonism. Furthermore, it inhibits NF-κB activation, which downregulates MMP-9 expression, thereby impairing the migration and invasion of breast cancer cells. Glaucine is relevant for research applications in asthma and breast cancer. -
PDE4 Inhibitor
LT-104A is a selective phosphodiesterase 4 (PDE4) inhibitor that effectively elevates intracellular cyclic AMP (cAMP) levels, exhibiting an EC50 of 1.9 μM and inhibiting PDE4D3 activity with an IC50 of 9.3 μM. By activating the cAMP-PKA-CREB anti-inflammatory signaling pathway, LT-104A suppresses expression of NF-κB-related genes such as Il1b and Nos2. This compound is valuable for research focused on inflammation-related diseases and therapeutic interventions aimed at modulating inflammatory responses. -
PI3K/Akt Inhibitor, MAPK Inhibitor, NF-κB Inhibitor, Nrf2/ARE Activator
JRN73958 is a potent inhibitor of the PI3K/Akt, MAPK, and NF-κB signaling pathways. This compound effectively reduces LPS/IFNγ-induced activation of these pathways, making it a valuable tool for investigating their roles in cancer biology, particularly in leukemia research. Additionally, JRN73958 acts as an Nrf2/ARE activator, further expanding its utility in studies related to oxidative stress and cell survival mechanisms. -
p38 MAPK Inhibitor
Ganoderterpene A is a potent inhibitor of p38 MAPK, demonstrating significant anti-inflammatory and anti-apoptotic activity. It effectively attenuates LPS-induced inflammation and apoptosis by suppressing the MAPK and TLR-4/NF-κB signaling pathways in BV-2 cells. This compound is valuable for research applications focused on neuroinflammation and cellular stress responses. -
MAPK/NF-κB Inhibitor
Masticadienonic acid is a selective inhibitor of the MAPK pathway (including p38, ERK, and JNK) and the NF-κB signaling cascade, while also acting as an agonist of the Nrf2 pathway. This compound effectively reduces the release of proinflammatory cytokines such as TNFα, IL-1β, and IL-6, and it restores the expression of intestinal tight junction proteins, including ZO-1 and occludin. Its regulatory effects on intestinal flora and inflammation make it suitable for research applications in inflammatory bowel disease and leishmaniasis. -
NF-κB/MAPK Inhibitor
Isonardosinone is a nardosinone-type sesquiterpene that primarily targets the NF-κB and MAPK signaling pathways. It effectively inhibits the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in lipopolysaccharide-induced BV2 microglial cells, demonstrating significant anti-inflammatory activity. This compound is valuable for research applications focused on inflammation and neurodegenerative diseases. -
p38 MAPK Inhibitor
Anti-inflammatory agent 7 is a selective p38 MAPK inhibitor that modulates the NF-κB/MAPK signaling pathway to inhibit proinflammatory cytokine production. This reagent demonstrates significant anti-inflammatory activity in LPS-treated RAW 264.7 cells and in in vivo models, making it a valuable tool for studying inflammatory responses and developing therapeutic strategies for related diseases. -
PI3K/PIKK Inhibitor
PI3K/PIKK-IN-1 is a potent inhibitor of phosphoinositide 3-kinases (PI3K) and PI3-kinase-related kinases (PIKK). This compound is utilized in the development of antibody-drug conjugates (ADCs), making it valuable for therapeutic applications. It is particularly relevant in the research of various cancers, including breast cancer, multiple myeloma, Burkitt lymphoma, diffuse large B-cell lymphoma, and non-small cell lung cancer, aiding in the exploration of targeted cancer therapies. -
HDAC Inhibitor
HDAC-IN-54 is a potent histone deacetylase (HDAC) inhibitor, exhibiting IC50 values of 25 nM for human HDAC1, 66 nM for HDAC2, 6.5 nM for HDAC3, and 281 nM for HDAC6. This compound effectively induces acetylation of α-tubulin and histone H3, promoting cancer cell apoptosis, particularly in synergy with cisplatin. HDAC-IN-54 is relevant for research applications in head and neck cancer, ovarian cancer, and tongue squamous cell carcinoma. -
MyD88 Inhibitor
T6167923 is a selective inhibitor of MyD88-dependent signaling pathways, targeting the Toll/IL-1 receptor (TIR) domain of MyD88 to disrupt its homodimeric formation. This compound effectively inhibits NF-κB-mediated Staphylococcus enterotoxin AP (SEAP) activity, demonstrating notable anti-inflammatory effects with IC50 values of 2.7 μM for IFN-γ, 2.9 μM for IL-1β, 2.66 μM for IL-6, and 2.66 μM for TNF-α. T6167923 serves as a valuable tool in studying the role of MyD88 signaling in inflammatory responses and therapeutic interventions. -
Myd88 Inhibitor
MyD88-IN-1 is a potent inhibitor of MyD88, targeting the interaction between TLR4 and MyD88. By suppressing the NF-κB signaling pathway, MyD88-IN-1 demonstrates significant biological activity relevant to cancer and inflammatory research. This compound serves as a valuable tool for elucidating the role of MyD88 in various disease processes and therapeutic interventions. -
Influenza Virus Inhibitor
Amizon is an orally effective antiviral agent targeting the influenza virus. It inhibits viral replication and restricts RNA synthesis, while simultaneously reducing the mRNA expression of pro-inflammatory mediators such as COX-1, COX-2, NF-κB, TGF-β1, IL-1, and IL-6. Additionally, Amizon enhances the secretion and mRNA expression of the anti-inflammatory cytokine IL-10 and exhibits antioxidant properties, inhibiting the oxidative activity of macrophages. This compound is of interest in research focused on influenza and acute respiratory viral infections. -
Parasite Inhibitor
8-Deoxygartanin, a prenylated xanthone derived from Garcinia mangostana, serves as a selective inhibitor of butyrylcholinesterase (BChE). This compound demonstrates significant antiplasmodial activity, with an IC50 value of 11.8 μM against the W2 strain of Plasmodium falciparum. Additionally, 8-Deoxygartanin inhibits NF-κB (p65) activation, displaying an IC50 of 11.3 μM, making it a valuable reagent for research in parasitic infections and inflammation pathways. -
FIKK Inhibitor
GSK2181306A is a pan-FIKK inhibitor that exhibits an EC50 value of 0.16 μM for the inhibition of parasite growth. This compound is valuable for research focused on Plasmodium infections, enabling exploration of FIKK pathways in parasitic disease mechanisms and potential therapeutic interventions. -
HCV/HDAC6 Inhibitor
Nicoxamat, also known as N-Hydroxynicotinamide, functions as an inhibitor of hepatitis C virus (HCV) and selectively targets HDAC6. This compound exhibits antiviral activity against HCV, making it a useful tool in research on hepatitis C infection. Its role as an HDAC6 inhibitor further supports investigations into epigenetic regulation and potential therapeutic strategies. -
Syk Inhibitor
DBMB is a selective inhibitor of spleen tyrosine kinase (Syk) that effectively attenuates Syk kinase activity. Its mechanism of action involves the suppression of NF-κB signaling, leading to a decrease in the production of key inflammatory mediators, including nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB is suitable for investigations focused on inflammatory diseases and elucidating the role of Syk in immune response pathways. -
iNOS Inhibitor
Asperuloside is an iridoid compound derived from Hedyotis diffusa, primarily known for its role as an inducible nitric oxide synthase (iNOS) inhibitor. This compound exhibits notable anti-inflammatory properties by suppressing the NF-κB and MAPK signaling pathways. Asperuloside is valuable in studying inflammatory processes and developing therapeutic strategies for related diseases. -
NF-κB Inhibitor
Neocryptotanshinone is a potent NF-κB inhibitor derived from Salvia miltiorrhiza. This compound effectively suppresses lipopolysaccharide-induced inflammation by targeting and inhibiting the NF-κB and iNOS signaling pathways. It shows promise in research applications focused on inflammatory diseases and provides valuable insights into the mechanisms of immune response modulation. -
iNOS/Nf-Κb Inhibitor
Hymenoxin is a dual inhibitor of inducible nitric oxide synthase (iNOS) and nuclear factor kappa B (NF-κB), exhibiting IC50 values of 42.7 μM and 85.5 μM, respectively. This compound demonstrates the capacity to reduce oxidative stress by 16% at a concentration of 125 μg/mL. Hymenoxin is primarily utilized in research focused on inflammatory responses and related signaling pathways. Its inhibitory effects on key regulators make it valuable for studies investigating the roles of iNOS and NF-κB in various disease models.
